EAST-AFNET 4 (Early Rhythm Control in AFib)

Design

2,789 patients with newly diagnosed AFib (within 1 year) plus cardiovascular conditions, randomised to:

• Early rhythm control: antiarrhythmic drugs and/or catheter ablation aimed at sinus rhythm restoration and maintenance.
• Usual care: rate control alone, rhythm control only when symptoms persist despite rate control.

Median follow-up 5.1 years.

Findings

• Primary composite (CV death, stroke, hospitalisation for HF or ACS): 21% relative reduction with early rhythm control.
• Safety: serious adverse events were balanced between groups, though procedure-related events occurred more in the early-rhythm group.

Why it matters

Previous trials (AFFIRM, RACE) had shown no difference between rhythm-control and rate-control strategies in established AFib. The EAST-AFNET 4 difference was early intervention — within 1 year of AFib diagnosis — before atrial remodelling becomes irreversible.

The trial shifted guidelines toward earlier rhythm-control strategy (including ablation) in newly diagnosed AFib with cardiovascular comorbidities, rather than passive rate control.

Related entries

Atrial fibrillation, Heart failure, Sleep apnea.